All In Biotech

Drug Trial Radar · NCT00680095

Cumulative Irritation Test

21-day Cumulative Irritation Test

Last checked: Nov 20, 2026Latest source record: Apr 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Jan 22, 2007

Primary completion

Feb 19, 2007

Study completion Feb 19, 2007

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.

Conditions

  • Onychomycosis

Interventions

  • AN2690Drug

    AN2690 Solution, 2.5%, Daily for up to 21 days

  • AN2690Drug

    AN2690 Solution, 7.5%, Daily for up to 21 days

  • AN2690Drug

    AN2690 Solution, 5.0%, Daily for up to 21 days

  • AN2690 Solution, VehicleOther

    AN2690 Solution, Vehicle, Daily for up to 21 days

  • Sodium Lauryl Sulfate, 0.5%Other

    Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severe irritation (Grade 3 or 4) observed at any siteTime frame: Daily for 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Education and Research Foundation, Inc.

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.